Verition Fund Management LLC Prothena Corp Public LTD CO Transaction History

Verition Fund Management LLC

  • $23.6 Billion
  • Q4 2024

A detailed history of Verition Fund Management LLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Verition Fund Management LLC holds 39,422 shares of PRTA stock, worth $564,917. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,422
Holding current value
$564,917
% of portfolio
0.0%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
BUY
$11.95 - $18.35 $471,092 - $723,393
39,422 New
39,422 $545,000
Q2 2024

Aug 14, 2024
BUY
$19.54 - $26.15 $307,891 - $412,045
15,757 New
15,757 $325,000
Q1 2022

May 13, 2022
SELL
$30.27 - $49.22 $1.09 Million - $1.77 Million
-35,878 Closed
0 $0
Q4 2021

Feb 14, 2022
BUY
$42.11 - $73.26 $1.51 Million - $2.63 Million
35,878 New
35,878 $1.77 Million
Q4 2020

Feb 16, 2021
SELL
$10.12 - $13.94 $173,143 - $238,499
-17,109 Closed
0 $0
Q3 2020

Nov 16, 2020
SELL
$9.93 - $13.47 $862,172 - $1.17 Million
-86,825 Reduced 83.54%
17,109 $171,000
Q2 2020

Aug 14, 2020
BUY
$9.56 - $12.51 $229,009 - $299,677
23,955 Added 29.95%
103,934 $1.09 Million
Q1 2020

May 15, 2020
BUY
$7.54 - $15.77 $70,348 - $147,134
9,330 Added 13.21%
79,979 $856,000
Q4 2019

Feb 14, 2020
SELL
$7.48 - $17.01 $654,761 - $1.49 Million
-87,535 Reduced 55.34%
70,649 $1.12 Million
Q3 2019

Nov 14, 2019
BUY
$6.89 - $10.45 $1.09 Million - $1.65 Million
158,184 New
158,184 $1.24 Million

Others Institutions Holding PRTA

# of Institutions
198
Shares Held
44.5M
Call Options Held
601K
Put Options Held
259K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $672M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email